文献速递心外重症与机械循环支持

搏动性双心室辅助装置作为心脏移植桥接治疗心源性休克患者:单中心经验

Bridging patients in cardiogenic shock with a paracorporeal pulsatile biventricular assist device to heart transplantation-a single-centre experience.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该单中心回顾性分析纳入2004至2019年97例(90例成人、7例儿童)接受Berlin Heart Excor®搏动性双心室辅助装置作为心脏移植桥接的患者,其中84例为INTERMACS 1级。主要诊断为扩张型心肌病41例,支持期间48例死亡、49例成功桥接至移植,30天和1年生存率分别为70.1%和41.2%。作者认为在需要立即高心输出量以挽救已受损的肝肾功能时,该装置是心源性休克的合理治疗选择。

要点

  • 97例患者(90例成人、7例儿童)接受搏动性双心室辅助装置作为移植桥接,84例为INTERMACS 1级。
  • 支持期间肌酐从1.83 ± 0.79降至1.12 ± 0.67 mg/dl(P = 0.001),胆红素从3.94 ± 4.58降至2.65 ± 3.61 mg/dl(P = 0.084)。
  • 49例成功桥接至移植,48例死于支持期间;30天生存率70.1%,1年生存率41.2%。

核心结论

  • 作者认为,当需要立即高心输出量以挽救已受损的肝肾功能时,搏动性双心室辅助装置是心源性休克的合理治疗选择。

研究设计与样本

  • 回顾性单中心分析,纳入2004至2019年本机构所有接受Berlin Heart Excor®的患者,共97例(90例成人、7例儿童)。

主要发现

  • 84例为INTERMACS 1级(80例成人、4例儿童)。
  • 诊断包括扩张型心肌病(n=41)、缺血性心肌病(n=17)或心肌梗死(n=4)、心肌炎(n=15)、限制型心肌病(n=2)、心脏移植后移植物衰竭(n=7)、心脏切开术后心力衰竭(n=5)、围产期心肌病(n=3)、先天性心脏病(n=1)、瓣膜性心肌病(n=1)和中毒性心肌病(n=1)。
  • 平均支持时间63天(0-487天)。
  • 肌酐值从1.83 ± 0.79降至1.12 ± 0.67 mg/dl(P = 0.001),胆红素值从3.94 ± 4.58降至2.65 ± 3.61 mg/dl(P = 0.084)。
  • 脑卒中16例、出血15例、感染13例;48例死于支持期间,49例成功桥接至移植;30天生存率70.1%,1年生存率41.2%。

临床怎么用

  • 作者认为,在需要立即高心输出量以挽救已受损的肝肾功能时,搏动性双心室辅助装置可作为心源性休克的合理治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated the outcome of patients in cardiogenic shock receiving a paracorporeal pulsatile biventricular assist device as a bridge to transplantation. METHODS: We performed a retrospective single-centre analysis of all patients who received a Berlin Heart Excor® at our institution between 2004 and 2019. RESULTS: A total of 97 patients (90 adults, 7 paediatric) were analysed. Eighty-four patients were in Interagency Registry for Mechanically Assisted Circulatory Support level 1 (80 adults, 4 paediatric). Diagnoses were dilated cardiomyopathy (n = 41), ischaemic cardiomyopathy (n = 17) or myocardial infarction (n = 4), myocarditis (n = 15), restrictive cardiomyopathy (n = 2), graft failure after heart transplant (n = 7), postcardiotomy heart failure (n = 5), postpartum cardiomyopathy (n = 3), congenital heart disease (n = 1), valvular cardiomyopathy (n = 1) and toxic cardiomyopathy (n = 1). All patients were in biventricular heart failure and had secondary organ dysfunction. The mean duration of support was 63 days (0-487 days). There was a significant decrease in creatinine values after assist device implantation (from 1.83 ± 0.79 to 1.12 ± 0.67 mg/dl, P = 0.001) as well as a decrease in bilirubin values (from 3.94 ± 4.58 to 2.65 ± 3.61 mg/dl, P = 0.084). Cerebral stroke occurred in 16 patients, bleeding in 15 and infection in 13 patients. Forty-eight patients died on support, while 49 patients could be successfully bridged to transplantation. Thirty-day survival and 1-year survival were 70.1% and 41.2%, respectively. CONCLUSIONS: A pulsatile biventricular assist device is a reasonable therapeutic option in cardiogenic shock, when immediate high cardiac output is necessary to rescue the already impaired kidney and liver function of the patient.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Michel S, Buchholz S, Buech J, et al. Bridging patients in cardiogenic shock with a paracorporeal pulsatile biventricular assist device to heart transplantation-a single-centre experience. Eur J Cardiothorac Surg. 2022. PMID: 35020902. doi:10.1093/ejcts/ezab547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。